These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 19780723)

  • 21. Ovarian cancer screening.
    Kurjak A; Predanic M
    Curr Opin Obstet Gynecol; 1994 Feb; 6(1):67-74. PubMed ID: 8180353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ovarian cancer screening.
    Mackey SE; Creasman WT
    J Clin Oncol; 1995 Mar; 13(3):783-93. PubMed ID: 7884436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Role of Ca 125 in pelvic masses. Our experience].
    Rotondi M; Lauro C; Ammaturo FP; Guerriero V; Rasile M; Panariello S
    Minerva Ginecol; 2001 Feb; 53(1 Suppl 1):51-4. PubMed ID: 11526720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of ovarian cancer among women with a CA125 level of 35 U/ml or less.
    Kobayashi H; Yamada Y; Sado T; Sakata M; Yoshida S; Kawaguchi R; Kanayama S; Shigetomi H; Haruta S; Tsuji Y; Ueda S; Kitanaka T; Oi H
    Gynecol Obstet Invest; 2008; 65(2):133-8. PubMed ID: 17957102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Mass-screening for ovarian cancer by transvaginal ultrasonography--study on tumor markers at the second screening].
    Sato S; Sugo T; Maruyama H; Saito Y; Hasuo Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1994 Nov; 46(11):1247-53. PubMed ID: 7844443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ovarian cancer screening in women with a family history of breast or ovarian cancer.
    Lacey JV; Greene MH; Buys SS; Reding D; Riley TL; Berg CD; Fagerstrom RM; Hartge P
    Obstet Gynecol; 2006 Nov; 108(5):1176-84. PubMed ID: 17077240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Three-dimensional ultrasonography and power Doppler in ovarian cancer screening of asymptomatic peri- and postmenopausal women.
    Kurjak A; Prka M; Arenas JM; Sparac V; Merce LT; Corusic A; Ivancic-Kosuta M
    Croat Med J; 2005 Oct; 46(5):757-64. PubMed ID: 16158468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening Cuts Ovarian Cancer Mortality.
    Cancer Discov; 2016 Feb; 6(2):OF1. PubMed ID: 26758578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum CA 125 combined with transvaginal ultrasonography for ovarian cancer screening.
    Roupa Z; Faros E; Raftopoulos V; Tzavelas G; Kotrotsiou E; Sotiropoulou P; Karanikola E; Skifta E; Ardavanis A
    In Vivo; 2004; 18(6):831-6. PubMed ID: 15646829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ovarian status in healthy postmenopausal women.
    Healy DL; Bell R; Robertson DM; Jobling T; Oehler MK; Edwards A; Shekleton P; Oldham J; Piessens S; Teoh M; Mamers P; Taylor N; Walker F
    Menopause; 2008; 15(6):1109-14. PubMed ID: 18536617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients.
    Fehm T; Heller F; Krämer S; Jäger W; Gebauer G
    Anticancer Res; 2005; 25(3A):1551-4. PubMed ID: 16033059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system.
    Stirling D; Evans DG; Pichert G; Shenton A; Kirk EN; Rimmer S; Steel CM; Lawson S; Busby-Earle RM; Walker J; Lalloo FI; Eccles DM; Lucassen AM; Porteous ME
    J Clin Oncol; 2005 Aug; 23(24):5588-96. PubMed ID: 16110018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Summaries for patients. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement.
    Ann Intern Med; 2012 Dec; 157(12):I-56. PubMed ID: 23362519
    [No Abstract]   [Full Text] [Related]  

  • 35. Early detection of familial ovarian cancer.
    Dørum A; Kristensen GB; Abeler VM; Tropé CG; Møller P
    Eur J Cancer; 1996 Sep; 32A(10):1645-51. PubMed ID: 8983269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for ovarian cancer.
    MacDonald ND; Rosenthal AN; Jacobs IJ
    Ann Acad Med Singap; 1998 Sep; 27(5):676-82. PubMed ID: 9919339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ovarian cancer screening: a look at the evidence.
    Fields MM; Chevlen E
    Clin J Oncol Nurs; 2006 Feb; 10(1):77-81. PubMed ID: 16482731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ovarian cancer screening.
    Neesham D
    Aust Fam Physician; 2007 Mar; 36(3):126-8. PubMed ID: 17339973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Screening for ovarian cancer].
    Ohmura M
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):1958-63. PubMed ID: 1417004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ovarian cancer screening-ultrasound; impact on ovarian cancer mortality.
    Kamal R; Hamed S; Mansour S; Mounir Y; Abdel Sallam S
    Br J Radiol; 2018 Oct; 91(1090):20170571. PubMed ID: 30102555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.